Literature DB >> 24916780

Co-opting biology to deliver drugs.

Parisa Yousefpour1, Ashutosh Chilkoti.   

Abstract

The goal of drug delivery is to improve the safety and therapeutic efficacy of drugs. This review focuses on delivery platforms that are either derived from endogenous pathways, long-circulating biomolecules and cells or that piggyback onto long-circulating biomolecules and cells. The first class of such platforms is protein-based delivery systems--albumin, transferrin, and fusion to the Fc domain of antibodies--that have a long-circulation half-life and are designed to transport different molecules. The second class is lipid-based delivery systems-lipoproteins and exosomes-that are naturally occurring circulating lipid particles. The third class is cell-based delivery systems--erythrocytes, macrophages, and platelets--that have evolved, for reasons central to their function, to exhibit a long life-time in the body. The last class is small molecule-based delivery systems that include folic acid. This article reviews the biology of these systems, their application in drug delivery, and the promises and limitations of these endogenous systems for drug delivery.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Fc fusion; albumin; drug delivery; erythrocyte; exosome; folic acid; lipoprotein; macrophage; platelet; transferrin

Mesh:

Substances:

Year:  2014        PMID: 24916780      PMCID: PMC4251460          DOI: 10.1002/bit.25307

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  173 in total

Review 1.  Safety and utilization of blood components as therapeutic delivery systems.

Authors:  Tiffany Adams; Fars Alanazi; D Robert Lu
Journal:  Curr Pharm Biotechnol       Date:  2003-10       Impact factor: 2.837

2.  Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery.

Authors:  Ian R Corbin
Journal:  Methods Mol Biol       Date:  2013

3.  Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.

Authors:  Iontcho R Vlahov; Hari Krishna R Santhapuram; Paul J Kleindl; Stephen J Howard; Katheryn M Stanford; Christopher P Leamon
Journal:  Bioorg Med Chem Lett       Date:  2006-07-25       Impact factor: 2.823

4.  Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

Authors:  Felix Kratz; André Warnecke; Karin Scheuermann; Cornelia Stockmar; Jürgen Schwab; Peter Lazar; Peter Drückes; Norbert Esser; Joachim Drevs; Didier Rognan; Caterina Bissantz; Caterina Hinderling; Gerd Folkers; Iduna Fichtner; Clemens Unger
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

5.  Biochemically altered human erythrocytes as a carrier for targeted delivery of primaquine: an in vitro study.

Authors:  Fars K Alanazi; Gamal El-Din I Harisa; Ahmad Maqboul; Magdi Abdel-Hamid; Steven H Neau; Ibrahim A Alsarra
Journal:  Arch Pharm Res       Date:  2011-05-05       Impact factor: 4.946

6.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 7.  Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.

Authors:  Maria Chiara Rossi; Antonio Nicolucci
Journal:  Acta Biomed       Date:  2009-08

8.  Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis.

Authors:  C Fiehn; F Kratz; G Sass; U Müller-Ladner; E Neumann
Journal:  Ann Rheum Dis       Date:  2008-04-13       Impact factor: 19.103

Review 9.  Albumin as a versatile platform for drug half-life extension.

Authors:  Darrell Sleep; Jason Cameron; Leslie R Evans
Journal:  Biochim Biophys Acta       Date:  2013-04-29

Review 10.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more
  16 in total

1.  Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.

Authors:  Parisa Yousefpour; Lucie Ahn; Joel Tewksbury; Soumen Saha; Simone A Costa; Joseph J Bellucci; Xinghai Li; Ashutosh Chilkoti
Journal:  Small       Date:  2019-02-13       Impact factor: 13.281

Review 2.  Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.

Authors:  James R Kintzing; Maria V Filsinger Interrante; Jennifer R Cochran
Journal:  Trends Pharmacol Sci       Date:  2016-11-09       Impact factor: 14.819

3.  Interaction mechanism of novel fluorescent antifolates targeted with folate receptors α and β via molecular docking and molecular dynamic simulations.

Authors:  Cuihong Wang; Meiling Zhang; Shuhui Shi; Yue Jiang; Xuening Fei; Lijuan Liu; Dan Ye; Shouchao Zhang
Journal:  J Mol Model       Date:  2022-07-02       Impact factor: 1.810

Review 4.  Nanotechnology-based cell-mediated delivery systems for cancer therapy and diagnosis.

Authors:  Vahid Alimardani; Zahra Rahiminezhad; Mahvash DehghanKhold; Ghazal Farahavar; Mahboobeh Jafari; Mehdi Abedi; Leila Moradi; Uranous Niroumand; Mohammad Ashfaq; Samira Sadat Abolmaali; Gholamhossein Yousefi
Journal:  Drug Deliv Transl Res       Date:  2022-09-08       Impact factor: 5.671

5.  Cellular and exosome mediated molecular defense mechanism in bovine granulosa cells exposed to oxidative stress.

Authors:  Mohammed Saeed-Zidane; Lea Linden; Dessie Salilew-Wondim; Eva Held; Christiane Neuhoff; Ernst Tholen; Michael Hoelker; Karl Schellander; Dawit Tesfaye
Journal:  PLoS One       Date:  2017-11-08       Impact factor: 3.240

Review 6.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

Authors:  William R Strohl
Journal:  BioDrugs       Date:  2015-08       Impact factor: 5.807

7.  Immunoglobulin Free Light Chains and GAGs Mediate Multiple Myeloma Extracellular Vesicles Uptake and Secondary NfκB Nuclear Translocation.

Authors:  Giuseppe Di Noto; Marco Chiarini; Lucia Paolini; Elena Laura Mazzoldi; Viviana Giustini; Annalisa Radeghieri; Luigi Caimi; Doris Ricotta
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

Review 8.  Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells.

Authors:  Jinheng Wang; Yongjiang Zheng; Meng Zhao
Journal:  Front Pharmacol       Date:  2017-01-12       Impact factor: 5.810

9.  Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma.

Authors:  Peipei Xu; Huaqin Zuo; Bing Chen; Ruju Wang; Arsalan Ahmed; Yong Hu; Jian Ouyang
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

Review 10.  Extracellular Vesicle: An Emerging Mediator of Intercellular Crosstalk in Lung Inflammation and Injury.

Authors:  Heedoo Lee; Eric Abston; Duo Zhang; Ashish Rai; Yang Jin
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.